Trial Profile
Tolerability of escalating doses of AG 013 in patients with ulcerative oral mucositis due to induction chemotherapy for head and neck cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2013
Price :
$35
*
At a glance
- Drugs Dapatifagene navolactibac (Primary)
- Indications Stomatitis
- Focus Adverse reactions
- 26 Nov 2013 New trial record
- 24 Sep 2013 Results published in Cancer.